生物分析研究员
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2021-01-07
- 工作地点:广州-黄埔区
- 招聘人数:2人
- 工作经验:1年经验
- 学历要求:本科
- 职位月薪:8-32万/年
- 职位类别:生物工程/生物制药
职位描述
1. 良好的生物化学理论知识,熟练使用ELISA、MSD进行生物样品检测,并解决生物样品分析过程中的问题;
2. 负责生物分析PK,ADA及Nab方法开发和验证,确保分析方法满足SOP/指导原则;
3. 在SOP和GLP的指导下,确保分析工作依照实验方案进行;
4. 根据SOP准确、高效地完成分析实验、实验记录、报告书写,文件整理工作;
5. 参与撰写和修订部门的SOP。
任职要求:
1. 本科及以上学历,化学、生物化学或药学等相关专业;
2. 有生物、药代动力学以及分析化学工作经验,熟悉生物样品活性检测方法开发;
3. 熟悉ELISA及MSD;
4. 有大分子药物研究工作经验者、临床血浆样品检测经验者优先,具有强烈地主动学习品质的人优先;
5. 良好的沟通技巧及团队合作精神;
6. 英文优良,能够熟练地阅读专业英文文献及撰写必要的英文报告。
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)